Skip to content
ppharmaranks
Menu
Class IIOngoing

Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL) recall

FDA recall D-0651-2025 · initiated Sep 5, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Sep 24, 2025How we research

Sandoz Inc recalled Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL) in Sep 2025 — an FDA Class II recall (D-0651-2025) because cGMP deviations: Temperature excursion during transportation.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

cGMP deviations: Temperature excursion during transportation.

The manufacturing process itself

The FDA found the process itself out of compliance, usually before any defective product was identified.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Only the following 6 GTN Numbers for Lot # 110459 exp. date 02/28/2027: (01)00307813528104(21)10686040629319 (01)00307813528104(21)10687281435306 (01)00307813528104(21)10687409963168 (01)00307813528104(21)10701200331212 (01)00307813528104(21)10687325644911 (01)00307813528104(21)10687661160169

Quantity recalled: 6 vials

Details

Product
Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL), Hazardous Drug, Rx Only, Sterile, 5mL Multiple Dose Vial, Manufactured in Austria by Fareva Unterach GmbH for Sandoz Inc., Princeton, NJ 08540, Product of India, Vial NDC# 0781-3528-75, Carton NDC# 0781-3528-10.
Recalling company
Sandoz Inc
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Sep 5, 2025
FDA report date
Sep 24, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL) recalled?
Sandoz Inc recalled Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL) in Sep 2025 — an FDA Class II recall (D-0651-2025) because cGMP deviations: Temperature excursion during transportation. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL) recalled?
Per the FDA enforcement record, the reason for recall D-0651-2025 was: cGMP deviations: Temperature excursion during transportation.
Is a recalled Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL) dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL) are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Only the following 6 GTN Numbers for Lot # 110459 exp. date 02/28/2027: (01)00307813528104(21)10686040629319 (01)00307813528104(21)10687281435306 (01)00307813528104(21)10687409963168 (01)00307813528104(21)10701200331212 (01)00307813528104(21)10687325644911 (01)00307813528104(21)10687661160169. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0651-2025.

Source: openFDA Drug Enforcement record D-0651-2025

← All drug recalls